Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Non-Alcoholic Steatohepatitis Treatment Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The non-alcoholic steatohepatitis treatment market size has experienced rapid growth in recent years. It is expected to increase from $3.57 billion in 2025 to $4.98 billion in 2026, achieving a compound annual growth rate (CAGR) of 39.6%. Historically, this expansion can be linked to the growing prevalence of obesity, an increase in type 2 diabetes incidence, high consumption of processed foods, inadequate awareness regarding liver health, and limited treatment options for early-stage nash.
The non-alcoholic steatohepatitis treatment market size is anticipated to experience substantial growth over the upcoming years, projected to reach $18.97 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 39.7%. This expansion during the forecast period is driven by factors such as advancements in precision medicine, the development of novel NASH drugs, the adoption of digital health monitoring tools, government initiatives aimed at liver disease prevention, and increasing investment in liver disease research. Significant trends during this period are expected to include personalized lifestyle and diet management, advancements in non-invasive diagnostics, widespread fatty liver disease awareness programs, home-based liver health monitoring, and the development of novel pharmacological agents.
Get A Free Sample Report With In-Depth Market Insights:
Non-Alcoholic Steatohepatitis Treatment Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of insulin resistance has propelled the growth of the non-alcoholic steatohepatitis treatment market. Insulin resistance develops when muscles, fat, and liver cells do not adequately respond to insulin and struggle to absorb glucose from the blood, resulting in high blood sugar. These issues are linked to an unhealthy lifestyle, excessive sugar intake, and genetic predisposition. The prevalence of insulin resistance has expanded due to a rise in diabetes and other liver-related concerns, which are treated by non-alcoholic steatohepatitis treatment. For instance, in July 2025, PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported a significant increase in the prevalence rates of general obesity, abdominal obesity, severe obesity, and insulin resistance, with rates rising from 34.9% to 41.4%, 62.5% to 67.0%, 5.2% to 11.5%, and 22.5% to 30.2%, respectively. Therefore, the heightened prevalence of insulin resistance, driven by various liver and diabetes diseases, will stimulate the non-alcoholic steatohepatitis treatment market.
Non-Alcoholic Steatohepatitis Treatment Market Segment Landscape And Growth Outlook
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
Non-Alcoholic Steatohepatitis Treatment Market Trends Redefining Industry Growth
Leading companies within the non-alcoholic steatohepatitis treatment market are innovating products such as endogenous hormones to capture larger customer bases, achieve greater sales, and elevate revenue. Endogenous hormones are organic substances produced internally by the body’s various glands, tissues, or organs, playing vital roles in regulating physiological functions. An example of this is from September 2023, when 89bio Inc., a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin to treat individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is distinguished by its composition as an engineered glycoPEGylated analog of fibroblast growth factor 21. This specific formulation is currently being developed for addressing non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin’s unique aspect lies in its application of specialized glycoPEGylated technology, which ensures an extended half-life while retaining its full potency. This advanced methodology improves the product’s effectiveness in modulating key factors associated with lipid metabolism, NASH, and hypertriglyceridemia, including the reduction of triglycerides, glycemic control, steatosis, inflammation, and fibrosis.
Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
View The Full Non-Alcoholic Steatohepatitis Treatment Market Report:
Non-Alcoholic Steatohepatitis Treatment Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model